Sign in

Experimentally engineered mutations in a ubiquitin hydrolase, UBP-1, modulate in vivo resistance to artemisinin and chloroquine in Plasmodium berghei.

By N. Simwela and others
As resistance to artemisinins (current frontline drugs in malaria treatment) emerges in south East Asia (SEA), there is an urgent need to identify the genetic determinants and understand the molecular mechanisms underpinning such resistance. Such insights could lead to prospective interventions to contain resistance and prevent the eventual spread to... Show more
June 23, 2020
=
0
Loading PDF…
Loading full text...
Similar articles
Loading recommendations...
=
0
x1
Experimentally engineered mutations in a ubiquitin hydrolase, UBP-1, modulate in vivo resistance to artemisinin and chloroquine in Plasmodium berghei.
Click on play to start listening